[go: up one dir, main page]

CY1110448T1 - Ενωσεις ριλουζολης και λεβαντοπας για τη θεραπεια της ασθενειας του παρκινσον - Google Patents

Ενωσεις ριλουζολης και λεβαντοπας για τη θεραπεια της ασθενειας του παρκινσον

Info

Publication number
CY1110448T1
CY1110448T1 CY20081100457T CY081100457T CY1110448T1 CY 1110448 T1 CY1110448 T1 CY 1110448T1 CY 20081100457 T CY20081100457 T CY 20081100457T CY 081100457 T CY081100457 T CY 081100457T CY 1110448 T1 CY1110448 T1 CY 1110448T1
Authority
CY
Cyprus
Prior art keywords
rilozolis
lavandopas
units
treatment
disease
Prior art date
Application number
CY20081100457T
Other languages
English (en)
Inventor
Véronique Blanchard-Bregeon
Assunta Imperato
Saliha Moussaoui
Marie-Carmen Obinu
Michel Reibaud
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of CY1110448T1 publication Critical patent/CY1110448T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)

Abstract

Ένωση της λεβοντόπας και της ριλουζόλης ή ενός φαρμακευτικά αποδεκτού άλατος αυτής της ένωσης και χρήση αυτής της ένωσης για τη θεραπεία της νόσου του Πάρκινσον.
CY20081100457T 1998-04-24 2008-04-24 Ενωσεις ριλουζολης και λεβαντοπας για τη θεραπεια της ασθενειας του παρκινσον CY1110448T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9805153A FR2777781B1 (fr) 1998-04-24 1998-04-24 Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
EP99915809A EP1071422B1 (fr) 1998-04-24 1999-04-22 Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson

Publications (1)

Publication Number Publication Date
CY1110448T1 true CY1110448T1 (el) 2015-04-29

Family

ID=9525640

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100457T CY1110448T1 (el) 1998-04-24 2008-04-24 Ενωσεις ριλουζολης και λεβαντοπας για τη θεραπεια της ασθενειας του παρκινσον

Country Status (22)

Country Link
US (1) US6387936B1 (el)
EP (1) EP1071422B1 (el)
JP (1) JP2002512963A (el)
KR (1) KR100597170B1 (el)
AT (1) ATE386520T1 (el)
AU (1) AU768069B2 (el)
CA (1) CA2329636C (el)
CY (1) CY1110448T1 (el)
CZ (1) CZ300825B6 (el)
DE (1) DE69938179T2 (el)
DK (1) DK1071422T3 (el)
ES (1) ES2300141T3 (el)
FR (1) FR2777781B1 (el)
HU (1) HU228902B1 (el)
IL (1) IL139164A (el)
NO (1) NO329032B1 (el)
PT (1) PT1071422E (el)
RU (1) RU2225204C2 (el)
SK (1) SK285531B6 (el)
UA (1) UA70319C2 (el)
WO (1) WO1999055336A1 (el)
ZA (1) ZA200005758B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
EP1751312A4 (en) * 2004-05-21 2010-01-27 Univ Duke POLYMORPHISM IN TRYPTOPHAN HYDROXYLASE 2 REGULATING BRAIN SEROTONIN SYNTHESIS
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006060120A2 (en) * 2004-11-07 2006-06-08 Guilford F Timothy Liposomal formulation for oral administration of glutathione (reduced)
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
PL1948155T3 (pl) * 2006-06-28 2012-10-31 Chelsea Therapeutics Inc Kompozycje farmaceutyczne zawierające droksidopę
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
EP2468271B1 (en) * 2007-03-09 2014-07-16 Chelsea Therapeutics, Inc. Pharmaceutical composition comprising droxidopa for the treatment of fibromyalgia
EP2167066B1 (en) * 2007-05-07 2013-06-26 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders
BRPI0913642A2 (pt) * 2008-06-30 2015-11-24 Novartis Ag produtos de combinação
BRPI0921431A2 (pt) * 2008-11-06 2017-06-06 Biotie Therapies Ag método para tratar ou prevenir síndrome das pernas inquietas, composição farmacêutica, e, métodos para tratar ou prevenir distúrbios do sono, e para melhorar a quantidade do sono ou adequação do sono
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
ES2703255T3 (es) 2010-10-22 2019-03-07 Univ Duke Formulaciones de liberación lenta de 5-hidroxitriptófano como un complemento para terapias pro-serotoninérgicas
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма

Also Published As

Publication number Publication date
JP2002512963A (ja) 2002-05-08
NO329032B1 (no) 2010-08-02
DE69938179T2 (de) 2009-02-12
DK1071422T3 (da) 2008-06-16
HU228902B1 (en) 2013-06-28
ZA200005758B (en) 2002-01-17
FR2777781B1 (fr) 2004-04-09
NO20005290D0 (no) 2000-10-20
SK15882000A3 (sk) 2001-04-09
KR20010042960A (ko) 2001-05-25
ATE386520T1 (de) 2008-03-15
HUP0101645A3 (en) 2002-10-28
FR2777781A1 (fr) 1999-10-29
DE69938179D1 (de) 2008-04-03
CA2329636C (fr) 2009-09-08
EP1071422B1 (fr) 2008-02-20
SK285531B6 (sk) 2007-03-01
AU768069B2 (en) 2003-12-04
IL139164A (en) 2005-12-18
UA70319C2 (en) 2004-10-15
PT1071422E (pt) 2008-05-05
EP1071422A1 (fr) 2001-01-31
CZ20003908A3 (cs) 2001-02-14
KR100597170B1 (ko) 2006-07-05
CA2329636A1 (fr) 1999-11-04
AU3425599A (en) 1999-11-16
WO1999055336A1 (fr) 1999-11-04
NO20005290L (no) 2000-10-20
US6387936B1 (en) 2002-05-14
IL139164A0 (en) 2001-11-25
ES2300141T3 (es) 2008-06-01
HUP0101645A2 (hu) 2001-09-28
CZ300825B6 (cs) 2009-08-19
RU2225204C2 (ru) 2004-03-10

Similar Documents

Publication Publication Date Title
CY1110448T1 (el) Ενωσεις ριλουζολης και λεβαντοπας για τη θεραπεια της ασθενειας του παρκινσον
ATE369848T1 (de) Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
BR9808938A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
NZ501069A (en) Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
FI20000720A7 (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
CY1116988T1 (el) Βητα-l-2'-δεοξυ-νουκλεοζιτες για την θεραπεια ηπατιτιδας β
GB0108592D0 (en) Therapeutic agents
PL310475A1 (en) Application of anticonvulsants in treating neuro-aids diseases
GB0108591D0 (en) Therapeutic agents
BR9607212A (pt) Uso de uma nsaid-r em uma composição de proteção para o tratamento de cancer de colo retal
DK1296671T3 (da) Gabapentinanaloger til sövnforstyrrelser
DOP2002000451A (es) Nuevas ciclohexilsulfonas (agentes terapéuticos)
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
MY137595A (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for the treatment of cancer
RU94014833A (ru) Средство для лечения дегенеративных заболеваний суставов и околосуставных тканей
FI952953A7 (fi) Aineita metabolisten luustosairauksien hoitamiseen
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
ES2147576T3 (es) Utilizacion del efaroxan y de sus derivados para la preparacion de un medicamento destinado al tratamiento de la enfermedad de parkinson.
EA200000816A1 (ru) Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка
TR199700921T1 (xx) �nsanlarda g�r�len herpes-vir�s-8'in tedavisinde pensiklovir'in kullan�lmas�.
SE9501773D0 (sv) New use
ITMI20002172A0 (it) Specola divaricabile per trattamenti idroterapeutici dell'intestino